Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Farag Kameel D., holds the title of Interim CFO at Akari Therapeutics Plc.
On 2026-11-17, the insider transacted 2,873 shares.The shares were transacted at a weighted average price of $9.05 per share, resulting in a total market-relevant value of $26K.
Farag Kameel D. (Interim CFO) was granted $26K of $AKTX
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.